Human melanoma therapy in the SCID mouse:In vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments
Open Access
- 5 May 1999
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 81 (3) , 486-493
- https://doi.org/10.1002/(sici)1097-0215(19990505)81:3<486::aid-ijc25>3.0.co;2-p
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodiesNature Medicine, 1997
- Human Cytotoxic CD8+ T-Lymphocyte Clones Engraft in Severe Combined Immunodeficient (SCID) Mice but Show Diminished FunctionJournal of Immunotherapy, 1997
- T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.The Journal of Experimental Medicine, 1996
- In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.Journal of Clinical Investigation, 1996
- Targeting of peripheral blood T lymphocytesSpringer Seminars in Immunopathology, 1996
- Epitope selection and development of peptide based vaccines to treat cancerSeminars in Cancer Biology, 1995
- Tumor Heterogeneity and Immunotherapy of CancerImmunological Reviews, 1995
- Tumor Antigens Recognized by T LymphocytesAnnual Review of Immunology, 1994
- Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.The Journal of Experimental Medicine, 1994
- Alloreactive cytolytic T-cell clones preferentially recognize conformational determinants on histocompatibility antigens: analysis with genetically engineered hybrid antigens.Proceedings of the National Academy of Sciences, 1985